S-1 (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) is a dihydropyrimidine dehydrogenase (DPD)-inhibitory fluoropyrimidine (DIF), which showed the highest response rate among many oral anticancer agents against unresectable advanced carcinomas in phase II studies (Schoffski, 2004). The gene discussed is DPYD; the disease is carcinoma.